title: Selection of therapeutic modalities for hepatocellular carcinoma in patients with multiple hepatic lesions.
abstract: In the present study, we compared the survival of patients with multi tumor hepatocellular carcinoma (HCC) following their treatment with liver resection versus TAE. A total of 336 HCC patients were treated at Osaka University Hospital between 1980 and 1989. Of these, 140 patients underwent liver resection in the presence or absence of TAE and 173 subjects were treated with TAE alone. Our TAE protocol consisted of 50 mg Adriamycin, 3-5 ml lipiodol, and Gelfoam. The 1-, 3-, and 5-year survival values found for the liver resection group were 87.4%, 66.0%, and 47.4%, respectively, whereas the values calculated for the TAE group were 64.6%, 29.9%, and 15.8%, respectively. The survival of patients in the resection group was clearly better than that of subjects in the TAE group. Of the 140 patients who underwent resection, 36 cases were proven to have multiple lesions by histopathological examination. The 1- and 3-year survival values determined for this special group were 67.9% and 33.3%, respectively. Of the TAE cases, 113 were diagnosed as having multiple lesions by imaging examination, and their 1- and 3-year survival values were 59.7% and 24.9%, respectively. No significant differences in survival was found between these two different treatment modalities for these multiple-lesion cases. The results of this study indicate that it is unlikely that surgical resection is superior to TAE alone for the treatment of HCC patients with multiple lesions.
authors.affiliation: Department of Surgery II, Osaka University Medical School, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Monden
authors.forename: M
authors.initials: M
authors.lastname: Sakon
authors.forename: M
authors.initials: M
authors.lastname: Gotoh
authors.forename: T
authors.initials: T
authors.lastname: Kanai
authors.forename: K
authors.initials: K
authors.lastname: Umeshita
authors.forename: K S
authors.initials: KS
authors.lastname: Wang
authors.forename: M
authors.initials: M
authors.lastname: Sakurai
authors.forename: C
authors.initials: C
authors.lastname: Kuroda
authors.forename: J
authors.initials: J
authors.lastname: Okamura
authors.forename: T
authors.initials: T
authors.lastname: Mori
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D006528:Carcinoma, Hepatocellular / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D016461:Chemoembolization, Therapeutic; D003131:Combined Modality Therapy; D005260:Female; D006498:Hepatectomy; D006801:Humans; D008113:Liver Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D015996:Survival Rate; D014057:Tomography, X-Ray Computed